NASA Human Research Program

Arthroventions to Attend 2018 NASA Human Research Program Investigator’s Workshop

Arthoventions CEO, Eric Hoffman, and CMO, Dr. Richard Meehan, will be attending the 2018 NASA Human Research Program (HRP) Investigator’s Workshop January 22-25 in Galveston, TX. The workshop is the annual meeting for NASA-funded investigators intended to provide an opportunity for multi-disciplinary interaction and collaboration, and this year’s event is focused on the journey to Read more about Arthroventions to Attend 2018 NASA Human Research Program Investigator’s Workshop[…]

2017 Bone and Joint Expo Ultrasound Patient

Arthroventions Attends the 2017 Bone and Joint Expo

The Arthroventions team had the pleasure of attending the Arthritis Foundation’s third annual Bone and Joint Expo in Denver, CO. The Bone and Joint Expo is a patient-centric event that brings the best and most innovative presentations, products and services to individuals living with arthritis, bone and joint issues and other chronic health conditions. The Read more about Arthroventions Attends the 2017 Bone and Joint Expo[…]

AlloSource Lab Tissue Processing Facility

Arthroventions Tours AlloSource’s Tissue Processing Facility

Tissue Processing Facility                               Image courtesy of AlloSource The Arthroventions team had the pleasure of touring AlloSource’s tissue processing facility following the Colorado Bioscience Association’s BioBreakfast on September 28. AlloSource is a nonprofit organization founded in 1994 to honor and respect the gift Read more about Arthroventions Tours AlloSource’s Tissue Processing Facility[…]

Joint Injection Survey Preliminary Results Featured Image

Joint Injection Survey Preliminary Results – September 28, 2017

Over the past two weeks, Arthroventions has been collecting data from patients with joint diseases who have received joint injections and/or aspirations in an attempt to better understand the patient population while validating the clinical literature. Joint Injection Survey Preliminary Results Clinical literature indicates that 1 of 3 non-image-guided injections miss the joint space, leading Read more about Joint Injection Survey Preliminary Results – September 28, 2017[…]

Clinical Translation I-Corps @ CCTSI

Clinical Translation: From Hobby Lobby to Hospitals

Clinical Translation Arthroventions participated in the I-Corps Clinical Translation Program at CU Denver’s Colorado Clinical and Translational Sciences Institute (CCTSI) to better understand the KneeTap’s value proposition. Through the clinical translation program, the Arthroventions team had the opportunity to attend an intense, three week customer discovery experience, which allowed them to realize where gaps in Read more about Clinical Translation: From Hobby Lobby to Hospitals[…]

Arthroventions CMO, Dr. Richard Meehan, Receives Top Doctor Award

  Arthroventions’ very own Dr. Richard Meehan has received 5280 Magazine’s Top Doctor Award for the 11th time. Dr. Meehan has managed to earn the prestigious award for Rheumatology 11 out of 12 times since 2006 – the only missing year being 2008, when he was deployed to Iraq to research deployment-related lung disease. 5280 Read more about Arthroventions CMO, Dr. Richard Meehan, Receives Top Doctor Award[…]

Rick Scheuring pointing with Richard Meehan

Joint Injection & Aspiration Survey

Joint Injection & Aspiration Survey Dear Friends, We need your help in determining if there is a market need for better joint injections and aspirations. These are common out-patient procedures used to inject therapeutics to treat arthritis and joint pain, and are usually required before a patient is eligible for a joint replacement. Therapeutics that Read more about Joint Injection & Aspiration Survey[…]

Gene Therapy

Can Gene Therapy Stop the Progression of Osteoarthritis?

Kolon Life Sciences has attained approval in South Korea for a first-in-class cell-mediated gene therapy designed to treat osteoarthritis through regeneration of cartilage. “Kolon has said injection of Invossa has been shown in Phase III trials in Korea to ease the symptoms of about 84% of patients – while 88% of U.S. patients treated with Read more about Can Gene Therapy Stop the Progression of Osteoarthritis?[…]